(AOF) – Carmat, designer and developer of the most advanced total artificial heart in the world, announces the launch of a fundraising of approximately 30 million euros via the issue of new shares at a fixed price of 10 .50 euros per share. This fundraising is made up of a reserved offering for specialized and strategic investors and a public offering for retail investors via the PrimaryBid platform. It benefits from subscription commitments in the amount of 5.5 million euros.
Carmat plans to use the proceeds from the fundraising to support the development of its activities and in particular, the ramp-up of its production, the recovery and growth of Aeson’s sales and the launch of the Eficas clinical study in France.
The closing of the PrimaryBid offer is scheduled for December 7, 2022 at 11 p.m. and that of the reserved offer on December 8, 2022 before the opening of the markets, subject to early closing.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.